165 related articles for article (PubMed ID: 28083618)
1. Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.
Butrym A; Łacina P; Rybka J; Chaszczewska-Markowska M; Mazur G; Bogunia-Kubik K
Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):151-156. PubMed ID: 28083618
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment.
Butrym A; Rybka J; Łacina P; Gębura K; Frontkiewicz D; Bogunia-Kubik K; Mazur G
Leuk Res; 2015 Dec; 39(12):1462-6. PubMed ID: 26521987
[TBL] [Abstract][Full Text] [Related]
3. Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in multiple myeloma patients?
Bedewy AM; El-Maghraby SM
Eur J Haematol; 2014 Jan; 92(1):13-8. PubMed ID: 24118365
[TBL] [Abstract][Full Text] [Related]
4. Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
Greenberg AJ; Walters DK; Kumar SK; Rajkumar SV; Jelinek DF
Eur J Haematol; 2013 Dec; 91(6):504-13. PubMed ID: 23992230
[TBL] [Abstract][Full Text] [Related]
5. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
Heintel D; Rocci A; Ludwig H; Bolomsky A; Caltagirone S; Schreder M; Pfeifer S; Gisslinger H; Zojer N; Jäger U; Palumbo A
Br J Haematol; 2013 Jun; 161(5):695-700. PubMed ID: 23565715
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.
Jung SH; Choi HJ; Shin MG; Lee SS; Hwang EC; Jung TY; Cho MS; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
Ann Hematol; 2016 Oct; 95(10):1645-51. PubMed ID: 27365142
[TBL] [Abstract][Full Text] [Related]
7. The clinical significance of cereblon expression in multiple myeloma.
Schuster SR; Kortuem KM; Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Ahmann G; Kumar S; Rajkumar SV; Mikhael J; Laplant B; Champion MD; Laumann K; Barlogie B; Fonseca R; Bergsagel PL; Lacy M; Stewart AK
Leuk Res; 2014 Jan; 38(1):23-8. PubMed ID: 24129344
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma.
Bila J; Sretenovic A; Jelicic J; Tosic N; Glumac I; Fekete MD; Antic D; Balint MT; Markovic O; Milojevic Z; Radojkovic M; Trajkovic G; Puric M; Pavlovic S; Mihaljevic B
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):610-615. PubMed ID: 27618360
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Zhu YX; Kortuem KM; Stewart AK
Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948
[TBL] [Abstract][Full Text] [Related]
10. Modulation of cereblon levels by anti-myeloma agents.
Díaz-Rodríguez E; Pandiella A
Leuk Lymphoma; 2016; 57(1):167-76. PubMed ID: 25860244
[TBL] [Abstract][Full Text] [Related]
11. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
[TBL] [Abstract][Full Text] [Related]
12. Cereblon (
Iskierka-Jażdżewska E; Canzian F; Stępień A; Martino A; Campa D; Stein A; Krawczyk-Kuliś M; Rybicka-Ramos M; Kyrcz-Krzemień S; Butrym A; Mazur G; Jurczyszyn A; Zawirska D; Grząśko N; Tomczak W; Subocz E; Wątek M; Pasiarski M; Rymko M; Całbecka M; Druzd-Sitek A; Walewski J; Kruszewski M; Raźny M; Zaucha JM; Dudziński M; Gaj P; Robak T; Warzocha K; Jamroziak K
Leuk Lymphoma; 2020 Mar; 61(3):699-706. PubMed ID: 31746254
[TBL] [Abstract][Full Text] [Related]
13. IRF4 addiction in multiple myeloma.
Shaffer AL; Emre NC; Lamy L; Ngo VN; Wright G; Xiao W; Powell J; Dave S; Yu X; Zhao H; Zeng Y; Chen B; Epstein J; Staudt LM
Nature; 2008 Jul; 454(7201):226-31. PubMed ID: 18568025
[TBL] [Abstract][Full Text] [Related]
14. [Thalidomide, cereblon and multiple myeloma].
Ogura T
Nihon Rinsho; 2015 Jan; 73(1):149-55. PubMed ID: 25626321
[TBL] [Abstract][Full Text] [Related]
15. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.
Broyl A; Kuiper R; van Duin M; van der Holt B; el Jarari L; Bertsch U; Zweegman S; Buijs A; Hose D; Lokhorst HM; Goldschmidt H; Sonneveld P; ;
Blood; 2013 Jan; 121(4):624-7. PubMed ID: 23233657
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients.
Mlak R; Szudy-Szczyrek A; Mazurek M; Szczyrek M; Homa-Mlak I; Mielnik M; Chocholska S; Jankowska-Łęcka O; Małecka-Massalska T; Hus M
Br J Haematol; 2019 Sep; 186(5):695-705. PubMed ID: 31115923
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.
Kasamatsu T; Saitoh T; Ino R; Gotoh N; Mitsui T; Shimizu H; Matsumoto M; Sawamura M; Yokohama A; Handa H; Tsukamoto N; Murakami H
Hematol Oncol; 2017 Dec; 35(4):711-718. PubMed ID: 27405747
[TBL] [Abstract][Full Text] [Related]
18. IRF4 in multiple myeloma-Biology, disease and therapeutic target.
Agnarelli A; Chevassut T; Mancini EJ
Leuk Res; 2018 Sep; 72():52-58. PubMed ID: 30098518
[TBL] [Abstract][Full Text] [Related]
19. Allele-specific transcriptional regulation of IRF4 in melanocytes is mediated by chromatin looping of the intronic rs12203592 enhancer to the IRF4 promoter.
Visser M; Palstra RJ; Kayser M
Hum Mol Genet; 2015 May; 24(9):2649-61. PubMed ID: 25631878
[TBL] [Abstract][Full Text] [Related]
20. An intronic polymorphism of IRF4 gene influences gene transcription in vitro and shows a risk association with childhood acute lymphoblastic leukemia in males.
Do TN; Ucisik-Akkaya E; Davis CF; Morrison BA; Dorak MT
Biochim Biophys Acta; 2010 Feb; 1802(2):292-300. PubMed ID: 19897031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
